J. Jackson

Safety issues surrounding the use of aromatase inhibitors in breast cancer

J. Jackson, W. Miller, J. Dixon, 2003, Expert opinion on drug safety.

The therapeutic potential of aromatase inhibitors

W. Miller, J. Jackson, W. Miller, 2003, Expert opinion on investigational drugs.

Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.

M. Dowsett, D. Cameron, J. Dixon, 2004, European journal of cancer.

Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours

Naomi R Wray, N. Wray, H. Newbery, 2005, BMC Cancer.

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes

J. Dixon, W. Miller, L. Renshaw, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours

N. Wray, H. Newbery, C. Abbott, 2005, BMC Cancer.

Regulation of insulin-like growth factor-binding protein-1 synthesis and secretion by progestin and relaxin in long term cultures of human endometrial stromal cells.

S. Bell, J. Jackson, J. Jackson, 1991, The Journal of clinical endocrinology and metabolism.

Monoclonal Antibodies to Human Secretory “Pregnancy‐Associated Endometrial α1‐Globulin,” an Insulin‐Like Growth Factor Binding Protein: Characterization and Use in Radioimmunoassay, Western Blots, and Immunohistochemistry

S. Bell, R. James, J. Jackson, 1989, American journal of reproductive immunology.

Estrogen-independent cell proliferation occurs in the majority of estrogen receptor positive (ER+)/HER2 gene-amplified primary breast cancers: Evidence from a combined analysis of two independent neoadjuvant letrozole studies

M. Ellis, Y. Tao, W. Miller, 2005 .